UgHerald provides the most timely and comprehensive news coverage of Uganda. It covers a wide range of fields including politics, economy, society, culture, sports, as well as in-depth analysis of international relations and important domestic events. Whether you are concerned about local developments or international influences, this is the best source for the latest information on Uganda. We are committed to helping readers understand the current situation and future of Uganda through accurate, objective and in-depth news reports, while paying attention to the challenges and development opportunities it faces.

About Us

tanzania times : Latest News and In-depth Analysis
Contact Us

Investment

HomeInvestment

All News

Feb 26, 2025

NETSCOUT Applauded by Frost & Sullivan for Enabling Real-Time Visibility into Network Traffic with Competitive Strategies

NETSCOUT\'s solutions provide actionable intelligence through powerful deep packet inspection,behavioral analytics,and AI-driven insights

Feb 26, 2025

ADA and IPification Partner to Revolutionize Seamless Authentication for Digital Apps

SINGAPORE,Feb. 25,2025-- ADA,a leader in data and AI-driven digital transformation and all-in-one authentication solutions,and IPification,a pioneer in seamless mobile authentication,have announced t

Feb 26, 2025

Trip.com Group Limited Reports Unaudited Fourth Quarter and Full Year of 2024 Financial Results

SINGAPORE,Feb. 25,2025--Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) ("Trip.com Group" or the "Company"),a leading one-stop travel service provider of accommodation reservatio

Feb 26, 2025

Driving Impact: Southeast Asia as a Rising Force in Social Developments and Impact Investing

The region\'s rising maturity and rapid economic growth position it as a critical player in addressing social issues,

Feb 26, 2025

"The Future of Travel": Trip.com Group to Showcase Next-Gen Tech at ITB Berlin 2025

Trip.com Group to launch joint Technology Game Changers: Future Trends in Travel & Tourism report at ITB Berlin Press Conference

Feb 26, 2025

BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)

SHANGHAI,Feb. 23,2025-- BioCityBiopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist,SC0062,met the 12-week primary endpoint of a reduction in proteinuria in the

1 ... 55 56 57 58 59 60 61 ... 109